Terminology Service for NFDI4Health
JSON

Saracatinib

Go to external page http://purl.obolibrary.org/obo/NCIT_C48378

An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of Src and Abl, protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. This agent binds to and inhibits these tyrosine kinases and affects cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption. [ ]

Term info

Label

Saracatinib

Synonyms
  • 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-
  • AZD0530
  • N-(5-Chloro-1,3-Benzodioxol-4-Yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Oxan-4-yl)Oxy)Quinazolin-4-Amine
  • SARACATINIB
  • SRC Kinase Inhibitor AZD0530
  • Saracatinib
Subsets

NCIT_C116978, NCIT_C128784, NCIT_C63923, NCIT_C116977, NCIT_C157711, NCIT_C157712

ALT DEFINITION

A substance being studied in the treatment of some types of cancer. AZD0530 blocks enzymes needed for cancer growth. It is a type of tyrosine kinase inhibitor.

CAS Registry

379231-04-6

Chemical Formula

C27H32ClN5O5

Display Name

Saracatinib

FDA UNII Code

9KD24QGH76

Has Salt Form

http://purl.obolibrary.org/obo/NCIT_C95224

NSC Code

735464

Preferred Name

Saracatinib

Semantic Type

Pharmacologic Substance

UMLS CUI

C2828242

code

C48378